Literature DB >> 26912783

Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.

Johanna Karlsson1, Lucy Roalfe2, Harriet Hogevik3, Marta Zancolli2, Björn Andréasson4, David Goldblatt2, Christine Wennerås3.   

Abstract

Patients with multiple myeloma and other B cell disorders respond poorly to pneumococcal vaccination. Vaccine responsiveness is commonly determined by measuring pneumococcal serotype-specific antibodies by enzyme-linked immunosorbent assay (ELISA), by a functional opsonophagocytosis assay (OPA), or by both assays. We compared the two methods in vaccinated elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance (MGUS). Postvaccination sera from 45 patients (n= 15 from each patient group) and 15 control subjects were analyzed by multiplexed OPA for pneumococcal serotypes 4, 6B, 14, and 23F, and the results were compared to IgG and IgM antibody titers measured by ELISA. While there were significant correlations between pneumococcal OPA and IgG titers for all serotypes among the control subjects (correlation coefficients [r] between 0.51 and 0.85), no significant correlations were seen for any of the investigated serotypes in the myeloma group (r= -0.18 to 0.21) or in the group with Waldenstrom's macroglobulinemia (borderline significant correlations for 2 of 4 serotypes). The MGUS group resembled the control group by having good agreement between the two test methods for 3 of 4 serotypes (r= 0.53 to 0.80). Pneumococcal postvaccination IgM titers were very low in the myeloma patients compared to the other groups and did not correlate with the OPA results. To summarize, our data indicate that ELISA measurements may overestimate antipneumococcal immunity in elderly subjects with B cell malignancies and that a functional antibody test should be used specifically for myeloma and Waldenstrom's macroglobulinemia patients.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26912783      PMCID: PMC4820510          DOI: 10.1128/CVI.00654-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

1.  Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.

Authors:  Isabelle Henckaerts; David Goldblatt; Lindsey Ashton; Jan Poolman
Journal:  Clin Vaccine Immunol       Date:  2006-03

Review 2.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

3.  Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Authors:  Birgit Simell; Arja Vuorela; Nina Ekström; Arto Palmu; Antti Reunanen; Seppo Meri; Helena Käyhty; Merja Väkeväinen
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

4.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance.

Authors:  L M Pilarski; E J Andrews; H M Serra; J A Ledbetter; B A Ruether; M J Mant
Journal:  Am J Hematol       Date:  1989-02       Impact factor: 10.047

6.  Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.

Authors:  Charles E Rose; Sandra Romero-Steiner; Robert L Burton; George M Carlone; David Goldblatt; Moon H Nahm; Lindsey Ashton; Mitch Haston; Nina Ekström; Raili Haikala; Helena Käyhty; Isabelle Henckaerts; Nathalie Durant; Jan T Poolman; Phil Fernsten; Xinhong Yu; Branda T Hu; Kathrin U Jansen; Milan Blake; Elles R Simonetti; Peter W M Hermans; Brian D Plikaytis
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

7.  Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients.

Authors:  Deepali Kumar; Coleman Rotstein; Genevieve Miyata; Dianne Arlen; Atul Humar
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

8.  Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.

Authors:  Jeremy G Schenkein; Saeyoung Park; Moon H Nahm
Journal:  Vaccine       Date:  2008-08-13       Impact factor: 3.641

9.  Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma.

Authors:  Maja Hinge; Helene A S Ingels; Hans-Christian Slotved; Ingolf Mølle
Journal:  APMIS       Date:  2012-05-22       Impact factor: 3.205

Review 10.  Immunodeficiency and immunotherapy in multiple myeloma.

Authors:  Guy Pratt; Oliver Goodyear; Paul Moss
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

View more
  7 in total

1.  Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response.

Authors:  Michael A Thompson; Martin K Oaks; Maharaj Singh; Karen M Michel; Michael P Mullane; Husam S Tarawneh; Angi Kraut; Kayla J Hamm
Journal:  J Patient Cent Res Rev       Date:  2017-08-10

2.  Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.

Authors:  Adrian M Shields; Sian E Faustini; Marisol Perez-Toledo; Sian Jossi; Joel D Allen; Saly Al-Taei; Claire Backhouse; Lynsey A Dunbar; Daniel Ebanks; Beena Emmanuel; Aduragbemi A Faniyi; Mark Garvey; Annabel Grinbergs; Golaleh McGinnell; Joanne O'Neill; Yasunori Watanabe; Max Crispin; David C Wraith; Adam F Cunningham; Mark T Drayson; Alex G Richter
Journal:  BMJ Open Respir Res       Date:  2021-09

3.  Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.

Authors:  Adrian M Shields; Sian E Faustini; Marisol Perez-Toledo; Sian Jossi; Joel D Allen; Saly Al-Taei; Claire Backhouse; Lynsey Dunbar; Daniel Ebanks; Beena Emmanuel; Aduragbemi A Faniyi; Mark I Garvey; Annabel Grinbergs; Golaleh McGinnell; Joanne O'Neill; Yasunori Watanabe; Max Crispin; David C Wraith; Adam F Cunningham; Mark T Drayson; Alex G Richter
Journal:  medRxiv       Date:  2020-11-16

Review 4.  A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency.

Authors:  Elda Righi; Tolinda Gallo; Anna Maria Azzini; Fulvia Mazzaferri; Maddalena Cordioli; Mara Merighi; Evelina Tacconelli
Journal:  Infect Dis Ther       Date:  2021-03-09

5.  Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.

Authors:  Maria Gavriatopoulou; Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Alexandros Briasoulis; Sentiljana Gumeni; Panagiotis Malandrakis; Despina Fotiou; Magdalini Migkou; Foteini Theodorakakou; Evangelos Eleutherakis-Papaiakovou; Nikolaos Kanellias; Efstathios Kastritis; Ioannis P Trougakos; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2021-11-09

6.  Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study.

Authors:  Mathilde Bahuaud; Hélène Bodilis; Marion Malphettes; Anaïs Maugard Landre; Caroline Matondo; Didier Bouscary; Frédéric Batteux; Odile Launay; Jean-Paul Fermand
Journal:  Heliyon       Date:  2017-11-06

Review 7.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.